// App-Quantinova.ai

: Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Researchers

Presenter

  • Richa Manwani

Principal Investigators

  • Faye Sharpley

  • Shameem Mahmood

  • Sajitha Sachchithanantham

  • Helen Lachmann

  • Julian Gillmore

  • Carol Whelan

  • Philip Hawkins

  • Ashutosh D. Wechalekar

Medical Centers

  • National Amyloidosis Centre, University College London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • AL Amyloidosis

Biomarkers

  • N/A

Drug/Treatment

  • Bortezomib

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved